Pancreatic Neoplasms

"Pancreatic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).

Descriptor ID	D010190
MeSH Number(s)	C04.588.274.761 C04.588.322.475 C06.301.761 C06.689.667 C19.344.421
Concept/Terms	Pancreatic Neoplasms Pancreatic Neoplasms Neoplasm, Pancreatic Pancreatic Neoplasm Pancreas Neoplasms Neoplasm, Pancreas Neoplasms, Pancreas Pancreas Neoplasm Neoplasms, Pancreatic Cancer of Pancreas Cancer of Pancreas Pancreas Cancers Pancreas Cancer Cancer, Pancreas Cancers, Pancreas Pancreatic Cancer Cancer, Pancreatic Cancers, Pancreatic Pancreatic Cancers Cancer of the Pancreas

Below are MeSH descriptors whose meaning is more general than "Pancreatic Neoplasms".

Diseases [C]
Neoplasms [C04]
Neoplasms by Site [C04.588]
Digestive System Neoplasms [C04.588.274]
Pancreatic Neoplasms [C04.588.274.761]
Endocrine Gland Neoplasms [C04.588.322]
Pancreatic Neoplasms [C04.588.322.475]
Digestive System Diseases [C06]
Digestive System Neoplasms [C06.301]
Pancreatic Neoplasms [C06.301.761]
Pancreatic Diseases [C06.689]
Pancreatic Neoplasms [C06.689.667]
Endocrine System Diseases [C19]
Endocrine Gland Neoplasms [C19.344]
Pancreatic Neoplasms [C19.344.421]

Below are MeSH descriptors whose meaning is more specific than "Pancreatic Neoplasms".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Pancreatic Neoplasms" by people in this website by year, and whether "Pancreatic Neoplasms" was a major or minor topic of these publications.

Bar chart showing 99 publications over 21 distinct years, with a maximum of 10 publications in 2014 and 2016 and 2023

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2004	3	0	3
2005	1	2	3
2006	1	1	2
2007	2	2	4
2008	1	0	1
2009	3	0	3
2010	1	0	1
2011	4	0	4
2012	3	0	3
2013	6	0	6
2014	10	0	10
2015	8	0	8
2016	8	2	10
2017	7	0	7
2018	3	0	3
2019	7	0	7
2020	9	0	9
2021	2	0	2
2022	2	0	2
2023	10	0	10
2024	1	0	1

Below are the most recent publications written about "Pancreatic Neoplasms" by people in Profiles.

Yoshizawa M, Shiozaki A, Ashihara E. Depletion of DNTTIP2 Induces Cell Cycle Arrest in Pancreatic Cancer Cells. Cancer Genomics Proteomics. 2024 Jan-Feb; 21(1):18-29.

View in: PubMed
Zhang R, Peng X, Du JX, Boohaker R, Estevao IL, Grajeda BI, Cox MB, Almeida IC, Lu W. Oncogenic KRASG12D Reprograms Lipid Metabolism by Upregulating SLC25A1 to Drive Pancreatic Tumorigenesis. Cancer Res. 2023 11 15; 83(22):3739-3752.

View in: PubMed
Ingle K, LaComb JF, Graves LM, Baines AT, Bialkowska AB. AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor. PLoS One. 2023; 18(11):e0294065.

View in: PubMed
Zhong H, Liu S, Zhu J, Xu TH, Yu H, Wu L. Elucidating the role of blood metabolites on pancreatic cancer risk using two-sample Mendelian randomization analysis. Int J Cancer. 2024 Mar 01; 154(5):852-862.

View in: PubMed
Liu S, Zhong H, Zhu J, Wu Y, Deng Y, Wu L. Regulome-wide association study identifies genetically driven accessible regions associated with pancreatic cancer risk. Int J Cancer. 2024 Feb 15; 154(4):670-678.

View in: PubMed
King SD, Veliginti S, Brouwers MCGJ, Ren Z, Zheng W, Setiawan VW, Wilkens LR, Shu XO, Arslan AA, Beane Freeman LE, Bracci PM, Canzian F, Du M, Gallinger SJ, Giles GG, Goodman PJ, Haiman CA, Kogevinas M, Kooperberg C, LeMarchand L, Neale RE, Visvanathan K, White E, Albanes D, Andreotti G, Babic A, Berndt SI, Brais LK, Brennan P, Buring JE, Rabe KG, Bamlet WR, Chanock SJ, Fuchs CS, Gaziano JM, Giovannucci EL, Hackert T, Hassan MM, Katzke V, Kurtz RC, Lee IM, Malats N, Murphy N, Oberg AL, Orlow I, Porta M, Real FX, Rothman N, Sesso HD, Silverman DT, Thompson IM, Wactawski-Wende J, Wang X, Wentzensen N, Yu H, Zeleniuch-Jacquotte A, Yu K, Wolpin BM, Duell EJ, Li D, Hung RJ, Perdomo S, McCullough ML, Freedman ND, Patel AV, Peters U, Riboli E, Sund M, Tj?nneland A, Zhong J, Van Den Eeden SK, Kraft P, Risch HA, Amundadottir LT, Klein AP, Stolzenberg-Solomon RZ, Antwi SO. Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization. Cancer Epidemiol Biomarkers Prev. 2023 09 01; 32(9):1265-1269.

View in: PubMed
Inkoom A, Ndemazie NB, Smith T, Frimpong E, Bulusu R, Poku R, Zhu X, Han B, Trevino J, Agyare E. Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer. BMC Cancer. 2023 May 13; 23(1):435.

View in: PubMed
Zhong H, Liu S, Zhu J, Wu L. Associations between genetically predicted levels of blood metabolites and pancreatic cancer risk. Int J Cancer. 2023 07 01; 153(1):103-110.

View in: PubMed
Ndemazie NB, Bulusu R, Zhu XY, Frimpong EK, Inkoom A, Okoro J, Ebesoh D, Rogers S, Han B, Agyare E. Evaluation of Anticancer Activity of Zhubech, a New 5-FU Analog Liposomal Formulation, against Pancreatic Cancer. Int J Mol Sci. 2023 Feb 21; 24(5).

View in: PubMed
Telisnor G, DeRemer DL, Frimpong E, Agyare E, Allen J, Ricks-Santi L, Han B, George T, Rogers SC. Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans. J Natl Med Assoc. 2023 Apr; 115(2):164-174.

View in: PubMed

People

Explore

Similar Concepts

Top Journals